Prime Medicine, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Prime Medicine, Inc. (PRME) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $4.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-06
- Prime Medicine, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $4.87M, a 23.08% decline year-over-year.
- Prime Medicine, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $4.64M, a 18.25% decline year-over-year.
- Prime Medicine, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $12.75M, a 86.71% increase year-over-year.
- Prime Medicine, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $6.33M, a 21.83% decline year-over-year.
- Prime Medicine, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $29.27M, a 12.28% increase from fiscal 2024.
- Prime Medicine, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $26.07M, a 87.40% increase from fiscal 2023.
- Prime Medicine, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $13.91M, a 115.36% increase from fiscal 2022.
- Prime Medicine, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $6.46M, a 269.93% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.87M 10-Q · filed 2026-08-06 | $9.51M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $4.64M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $29.27M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | $12.75M 10-Q · filed 2025-11-07 | $19.07M derived: sum of 2 quarters · filed 2026-08-06 | $24.75M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $6.33M 10-Q · filed 2026-08-06 | $12.01M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $5.68M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $26.07M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $6.83M 10-Q · filed 2025-11-07 | $14.92M derived: sum of 2 quarters · filed 2025-11-07 | $20.13M derived: sum of 3 quarters · filed 2025-11-07 | ||
| 2024-06-30 | $8.09M 10-Q · filed 2025-11-07 | $13.30M derived: sum of 2 quarters · filed 2025-11-07 | |||
| 2024-03-31 | $5.21M 10-Q · filed 2025-11-07 | ||||
| 2023-12-31 | $13.91M 10-K · filed 2025-02-28 | ||||
| 2023-09-30 | $4.22M 10-Q · filed 2024-11-12 | $7.80M derived: sum of 2 quarters · filed 2024-11-12 | $9.48M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $3.58M 10-Q · filed 2024-11-12 | $5.26M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $1.68M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $6.46M 10-K · filed 2024-03-01 | ||||
| 2022-09-30 | $1.42M 10-Q · filed 2023-11-03 | $2.76M derived: sum of 2 quarters · filed 2023-11-03 | $3.89M derived: sum of 3 quarters · filed 2023-11-03 | ||
| 2022-06-30 | $1.35M 10-Q · filed 2023-11-03 | $1.34M 10-Q · filed 2022-11-14 | $2.47M derived: sum of 2 quarters · filed 2023-11-03 | ||
| 2022-03-31 | $1.12M 10-Q · filed 2023-11-03 | ||||
| 2021-12-31 | $1.75M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $339.00K 10-Q · filed 2022-11-14 | $433.00K derived: sum of 2 quarters · filed 2022-11-14 | $639.00K derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $94.00K 10-Q · filed 2022-11-14 | $300.00K derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-03-31 | $206.00K 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $391.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |